J&J Diabetes Drug Effective But Carries Risks, FDA Says

Law360, New York (January 8, 2013, 7:38 PM EST) -- The U.S. Food and Drug Administration raised concerns about safety risks in a new diabetes drug Johnson & Johnson is seeking approval for, directing an advisory committee this week to pay close attention to cardiovascular and bone risks, even as the agency said the drug is effective at lowering blood sugar.

An FDA advisory committee is meeting Thursday to consider whether to recommend that the agency approve the drug, canagliflozin, to treat type 2 diabetes. On Tuesday, the agency released its draft review of the drug...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.